Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Tests oral ICP-488 tablets against placebo for plaque psoriasis

Tests an oral tablet, ICP-488, in adults with moderate to severe plaque psoriasis.

Plain-language title generated from the registry record
Registry title: Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Key facts

Where
Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Jingzhou, Jinhua, Kunming, Lianyungang, Liuzhou, Luoyang, Nanchang, Nanjing, Nanyang, Ningbo, Sanmenxia, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Wuhu, Xi'an, Xi’an, and Zhengzhou, ChinaSee the 46 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT06842199, who can take part

Where in China

  • Beijing Chao-Yang Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
  • Beijing Friendship Hospital, Capital Medical UniversityBeijing, ChinaNo longer taking part
  • Beijing Tongren Hospital CMUBeijing, ChinaNo longer taking part
  • Peking University Third HospitalBeijing, ChinaNo longer taking part
  • The First Hospital of Jilin UniversityChangchun, ChinaNo longer taking part
  • The Second Xiangya Hospital of Central SouthChangsha, ChinaNo longer taking part
  • Xiangya Hospital of Central South UniversityChangsha, ChinaNo longer taking part
  • The First People's Hospital Of ChangzhouChangzhou, ChinaNo longer taking part
  • Affiliated Hospital of Chengde Medical UniversityChengde, ChinaNo longer taking part
  • Chengdu Second People's HospitalChengdu, ChinaNo longer taking part
  • Sichuan Provincial People's HospitalChengdu, ChinaNo longer taking part
  • Chongqing Traditional Chinese Medicine HospitalChongqing, ChinaNo longer taking part
  • The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaNo longer taking part
  • Fujian Medical University Union HospitalFuzhou, ChinaNo longer taking part
  • The First Affiliated Hospital of Fujian Medical UniversityFuzhou, ChinaNo longer taking part
  • First Affiliated Hospital Of Gannan Medical UniversityGanzhou, ChinaNo longer taking part
  • Dermatology Hospital of Southern Medical UniversityGuangzhou, ChinaNo longer taking part
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, ChinaNo longer taking part
  • The Affiliated Hospital of Guizhou Medical UniversityGuiyang, ChinaNo longer taking part
  • The Second Affiliated Hospital Zhejiang University School of MedicineHangzhou, ChinaNo longer taking part
  • The 2nd Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNo longer taking part
  • The First Affiliated Hospital of Anhui Medical UniversityHefei, ChinaNo longer taking part
  • Qilu Hospital of Shandong UniversityJinan, ChinaNo longer taking part
  • Jingzhou Central HospitalJingzhou, ChinaNo longer taking part
  • The Fourth Affiliated Hospital Zhejiang University School of MedicineJinhua, ChinaNo longer taking part
  • The First Affiliated Hospital of Kunming Medical UniversityKunming, ChinaNo longer taking part
  • The First People's Hospital of LianyungangLianyungang, ChinaNo longer taking part
  • Liuzhou People's HospitalLiuzhou, ChinaNo longer taking part
  • The Second Affiliated Hospital of Henan University of Science and TechnologyLuoyang, ChinaNo longer taking part
  • Dermatology Hospital of Jiangxi ProvinceNanchang, ChinaNo longer taking part
  • Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical CollegeNanjing, ChinaNo longer taking part
  • Nanyang Central HospitalNanyang, ChinaNo longer taking part
  • The First Affiliated Hospital of Ningbo UniversityNingbo, ChinaTaking people
  • Sanmenxia Central HospitalSanmenxia, ChinaNo longer taking part
  • Huashan Hospital, Fudan UniversityShanghai, ChinaNo longer taking part
  • Shanghai Skin Disease Hospital skin Disease of tongji UniversityShanghai, ChinaNo longer taking part
  • Northeast International HospitalShenyang, ChinaNo longer taking part
  • The Second Hospital of Hebei Medical UniversityShijiazhuang, ChinaNo longer taking part
  • Taiyuan Central HospitalTaiyuan, ChinaNo longer taking part
  • Tianjin Academy of Traditional Chinese Medicine Affiliated HospitalTianjin, ChinaNo longer taking part
  • The First Affiliated Hospital of Wenzhou Medical UniversityWenzhou, ChinaNo longer taking part
  • Wuhan Hospital of Traditional Chinese and Western Medicine (Wuhan No.1 Hospital)Wuhan, ChinaNo longer taking part
  • the Second Affiliated Hospital of Wannan Medical CollegeWuhu, ChinaNo longer taking part
  • The Second Affiliated Hospital of Xi'an Jiaotong UniversityXi'an, ChinaNo longer taking part
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityXi’an, ChinaTaking people
  • Henan Provincial People's HospitalZhengzhou, ChinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Beijing InnoCare Pharma Tech Co., Ltd.
Trial code
NCT06842199
Record updated
9 February 2026
Original description
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.Read full original descriptionShow less

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Oral ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.

Inclusion: Eligible subjects must meet all of the following criteria:; Subjects voluntarily participate in this study and have signed informed consent; Male or female subjects between the ages of 18 and 75 (including the threshold) at the time of signing the ICF; History of plaque psoriasis ≥6 months at baseline; Subjects need to receive systemic therapy and/or phototherapy; The following three criteria were met: a) psoriasis Area and Severity index (PASI) score ≥12; b) Psoriasis affected body surface area (BSA) ≥10%; c) Static physician overall assessment (sPGA) ≥3 scores.

Exclusion: Subjects with concurrent skin diseases that the investigator believes would interfere with the study assessments; Received related treatment within the time window specified in the protocol; An interval of less than 5 half-lives or 28 days (if any available half-life data) from the last dose of a strong CYP1A2/CYP3A4 inhibitor or inducer, or a plan to use concurrently medications with strong CYP1A2/CYP3A4 inhibitory or inductive effect during study participation; Presence of infection or immune-related disease; Subjects with a history of TB or at risk for TB; A history of severe drug allergies; Any other conditions in which the investigator considers it unsuitable for the subject to participate in this study; The investigator has determined that there are clinically significant test results and that participation in this trial would pose an unacceptable risk to patients; Or the laboratory values of the subjects in the screening period meet the criteria specified in the protocol; The diagnosis was non-plaque psoriasis; Pregnant or lactating women, or women who plan to become pregnant during study participation.

ClinicalTrials.gov NCT06842199